Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche announces partnership on HPV-disease vaccine

Roche announces partnership on HPV-disease vaccine

11th April 2007

Roche has announced that it has signed a worldwide collaboration agreement with Transgene for the development and commercialisation of products from its vaccine programme to tackle human papilloma virus (HPV)-mediated diseases.

Under the terms of the agreement, Roche will pay Transgene an initial sum of 13 million euros (8.83 million pounds) and an additional ten million euros as a milestone fee relating to the planning of phase III trials of the compound, with further payment of up to 195 million on attaining other landmarks in addition to escalating royalty sales.

In exchange, Roche will be granted an exclusive license for TG 4001 and other therapeutic vaccines currently in development for HPV-mediated diseases. Roche will fund all development costs of the compound.

Peter Hug, global head of pharma partnering at Roche, said: “Transgene’s expertise in viral vaccine therapeutics complements our core capabilities in oncology and virology drug development.”

He added that Roche is a leading firm in HPV detection and in vitro diagnostics in general, with this partnership potentially expanding into an integrated approach to personalised medicine.

Earlier this month, Roche announced the acquisition of privately-held Therapeutic Human Polyclonals to expand the company’s research efforts in therapeutic antibodies.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.